8-K ·Filed Jul 30, 2026

TEM

Tempus AI, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001193125-26-326083
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong beat, first GAAP profitable quarter, raised guidance, and accelerating operational metrics (Oncology volume, MRD, Insights) are clear positives. The ~$1.5B Personalis acquisition adds a leading MRD technology but introduces integration risk and near-term dilution. Monitor the Q3 2026 call for updates on Personalis deal closure (expected late Q4 2026/early 2027) and any changes to the ~$65M Adjusted EBITDA guidance.

DirectionBullish
Confidencehigh
Horizonweeks
Latest settled — T+20d
TEM ▲ +45.98% at T+20d
LONG call ✓ call won +45.98% · α vs SPY +42.99% · entry $43.87 → $64.04
Next anchor: T+60d in 21d
Latest observation: T+43 +81.02% FF3 residual α
Entry anchored
Jul 30, 04:01 PM ET
via exchange tick
T+1d
+4.97%
call +4.97% · α +3.54%
$46.05
settled 2mo ago
T+5d
+18.65%
call +18.65% · α +15.13%
$52.05
settled 8w ago
T+20d
+45.98%
call +45.98% · α +42.99%
$64.04
settled 5w ago
T+60d
—
call — · α —
—
in 21d

Price Chart

Loading chart...

Executive Summary

Tempus AI reported Q2 2026 revenue of $382.5M (+22% YoY), beating consensus of $379.5M, and a non-GAAP net loss per share of -$0.04, beating the consensus estimate of -$0.15. The company achieved its first GAAP net income quarter ($5.6M), generated positive Adjusted EBITDA of $8.0M, and raised full-year revenue guidance to $1.595-$1.605B. The quarter was highlighted by strong operational metrics including 31% oncology volume growth, 36% Insights revenue growth, and ~$200M in new Data & Applications bookings, alongside the announced acquisition of Personalis for ~$1.5B.

Key Financial Metrics

EPS
$-0.04
est $-0.15 · +73.3%
Revenue
$382.5M
est $379.5M · +0.8% · +22.0% YoY
Rating
strong beat
Guidance
$1.595B-$1.605B
raised
Gross Margin
64.4%

Key Facts

  • Total revenue of $382.5M, up 22% YoY, beating consensus of $379.5M.
  • Non-GAAP net loss per share of -$0.04, beating consensus estimate of -$0.15 (73.6% beat).
  • First GAAP net income quarter of $5.6M, compared to a net loss of -$42.8M in Q2 2025.
  • Adjusted EBITDA of $8.0M, compared to -$5.6M in Q2 2025.
  • Raised full-year 2026 revenue guidance to $1.595-$1.605 billion (~25% annual growth).
  • Oncology volume grew 31% YoY; MRD volume reached 9,000 tests (up from 6,500 last quarter).
  • Data Licensing & Modeling (Insights) revenue grew 36% YoY; signed ~$200M in new Data & Applications licenses.
  • Announced definitive agreement to acquire Personalis for ~$1.5B enterprise value.
  • Completed a $460M offering of 0.0% convertible senior notes due 2032; cash and marketable securities of $820.7M.

Financial Impact

Revenue beat consensus by ~$3M; EPS beat by ~$0.11. Raised FY2026 revenue guidance by $5M at the midpoint. The ~$1.5B Personalis acquisition represents a significant strategic investment.

revenueepsebitdaguidancecash

Risk Factors

  • Integration risk and potential dilution from the ~$1.5B Personalis acquisition.
  • Operating cash flow remains negative (-$80.8M in H1 2026), though improving.
  • Revenue growth decelerated to 22% YoY from 36% YoY in Q1 2026, partly due to the Ambry acquisition anniversary.
  • GAAP net income was driven by $98.5M in unrealized gains on marketable securities, which is non-recurring.

Market Snapshot

Exchange
Nasdaq
Sector
Services-Computer Programming, Data Processing, Etc.
Analyst Consensus
63% bullish (24 analysts)

Investment Themes

Software & IT

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-326083
Document: tem-20260730.htm0001193125-26-326083
Document: 0001193125-26-326083-index-headers.html0001193125-26-326083
Document: 0001193125-26-326083-index.html0001193125-26-326083
Document: 0001193125-26-326083.txt0001193125-26-326083
8-K Data (Synthetic)0001193125-26-326083
30 reports for TEM
Performance horizon
91% Hit rate 10 of 11 directional calls best @ T+20▲ +20.52%Mar 2, 2026
Filters
Rows
Reports for TEM — sortable, filterable
TypeNow
Sep 3, 2026
28d ago
Insider Cluster
NEUTRAL ★ 2/10
$64.62 $62.21▼ −3.73%▼ −2.52%$76.84 (+18.91%)
Sep 3, 2026
28d ago
Insider Cluster
NEUTRAL ★ 2/10
$64.62 $62.21▼ −3.73%▼ −2.52%$76.84 (+18.91%)
Sep 1, 2026
4w ago
Insider Cluster
NEUTRAL ★ 4/10
$62.27 $61.28▼ −1.59%▼ −1.67%$76.84 (+23.40%)
Aug 28, 2026
5w ago
Insider Cluster
BEARISH ★ 4/10
$64.04 $64.62▼ −0.91%▼ −0.80%$76.84 (−19.99%)
Aug 25, 2026
5w ago
144
BEARISH ★ 5/10
$68.48 $61.94▲ +9.55%▲ +9.43%$76.84 (−12.21%)
Aug 25, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$68.73 $62.27▼ −9.40%▼ −8.86%$76.84 (+11.80%)
Aug 21, 2026
6w ago
Insider Cluster
BEARISH ★ 6/10
$72.69 $64.04▲ +11.90%▲ +12.37%$76.84 (−5.71%)
Aug 19, 2026
6w ago
144
NEUTRAL ★ 3/10
$66.65 $70.69▲ +6.06%▲ +4.95%$76.84 (+15.29%)
Aug 18, 2026
6w ago
Insider Cluster
BEARISH ★ 4/10
$49.36 $68.73▼ −39.24%▼ −39.44%$76.84 (−55.67%)
Aug 11, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$55.69 $49.36▼ −11.37%▼ −10.96%$76.84 (+37.98%)
Showing 10 of 30

US Market Status

Market Open — Closes in 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access